by
Lisa Chamoff, Contributing Reporter | October 29, 2018
From the October 2018 issue of HealthCare Business News magazine
Rosenthal said Mevion also is integrating cone beam CT and CT on rails with the system sometime this year.
“The ability to use that in a proton room has been slow to materialize,” Rosenthal said.
P-Cure Proton Therapy Solution
P-Cure
P-Cure has marketed its gantry-less solution, and the company is planning to soon publicize results from use of the P-Cure system on patients being treated for lung, brain, eye and other types of cancer at the Northwestern Medicine Chicago Proton Center.
“The objective is to show … that patients can be treated even better without a gantry, in the seated position,” said Michael Marash, P-Cure’s chief executive officer. “When a patient is seated, the magnitude of the inner organ motion is minimized, enabling it to direct the beam to the tumor with much greater precision. There are also fewer equipment and construction costs, as a gantry needs three floors.”
At the Chicago center, P-Cure enabled treating in their open registry study. Next year, the company will look to show the effects of the system on treating several other tumor sites including, head and neck, breast, and liver cancers.
The company is also starting to explore international markets and has received a positive response from facilities in India and China, Marash said. The company is building a new facility in the center of Israel to ship both west and east.
ProTom International Holding Corporation
ProTom has made moves into the Asia Pacific market and was recently awarded the contract for the Australian Bragg Centre for Proton Therapy, the first proton therapy center in Australia, to be housed in a massive new health complex expected to break ground in the second quarter of next year in Adelaide.
“The U.S. market is more mature,” said Stephen Spotts, chief executive officer of ProTom International. “As cancer providers are looking at adding proton therapy, more providers are looking at single room systems.”
ProTom's Radiance 330 Proton Therapy System – which received FDA clearance in March 2014 – uses one synchrotron accelerator for multiple rooms, which is different from the company’s competitors, except for Hitachi, Spotts said. The center in South Australia is using renewable energy, which is one of the reasons they chose ProTom, which uses a synchrotron, with varied acceleration levels, as opposed to a cyclotron, where the acceleration is constant.
